Skip to main content
TipRanks
Go Ultimate75% OFF

WIN-Partners Co., Ltd. (3183) AI Stock Analysis

0 Followers
JP:3183

WIN-Partners Co., Ltd.

(TSE/TYO:3183)

Select Model
Rating:62Neutral
Price Target:JPY 1,355.00â–²(11.61% Upside)
Action:reiterated
Date:11/06/26

WIN-Partners earns a moderate score built on financial stability rather than growth firepower. The company's near debt-free balance sheet, steadily compounding revenue and growing equity base provide genuine defensive appeal, but razor-thin net margins of around 2.4%, mid-single-digit ROE and a history of volatile — at times negative — free cash flow cap the upside. Valuation is supportive, with a low P/E of 13.7 and an above-average 4.23% dividend yield offering income-oriented investors a reasonable entry point. The main drag is technical: negative MACD, a weak RSI of 34 and a share price still below its 200-day average suggest the market has yet to regain conviction, although the stock is holding above its shorter-term moving averages. Overall, this is a low-beta, income-tilted holding suited to investors prioritising stability over returns.

Positive Factors
Consistent revenue growthSustained revenue growth across multiple years indicates continued demand for the company’s medical distribution activities. This provides a durable base for maintaining scale, supporting operating earnings, and funding future business needs even though distributor margins remain relatively modest.
Negative Factors
Thin distributor marginsLow and slightly declining margins leave limited room to absorb higher operating costs, pricing pressure, or execution setbacks. Because small changes in gross profitability can materially affect earnings for a distributor, sustained margin softness could constrain long-term profit expansion.

WIN-Partners Co., Ltd. (3183) vs. iShares MSCI Japan ETF (EWJ)

-10%-5%0%5%10%15%20%25%30%JP:3183-3.36%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 33.38B
Dividend Yield
4.45%
Average Volume (3M)
30.37K
Price to Earnings (P/E)
13.4
Beta (1Y)
0.51
Revenue Growth
13.99%
EPS Growth
17.93%
Country
Japan
Employees
653
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

WIN-Partners Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1973 and headquartered in Tokyo, Japan, WIN-Partners Co., Ltd. leverages its subsidiaries to distribute a comprehensive range of medical devices to healthcare institutions, primarily across Japan. Its diverse product offerings include...

WIN-Partners Co., Ltd. Financial Statement Overview

Summary

A solid but unspectacular financial profile. The balance sheet is the standout strength (score 75): essentially debt-free through FY2025 with only a negligible debt-to-equity ratio (~0.03) projected for FY2026, steadily rising equity (¥21.1B to ¥24.1B), and a conservative equity-to-asset ratio of 46-52%. The income statement (score 58) shows dependable revenue growth from ¥62.1B in FY2021 to ¥81.4B in FY2025 with ¥90.4B projected for FY2026 (~7.7% growth), but profitability is thin and slowly compressing — net margins of just 2.4-2.9% and EBIT margins down from ~4.0% to ~3.3%. Cash flow (score 55) is the weakest link, with volatile operating cash flow (¥445M in FY2023 vs. ¥3.0B in FY2024) and negative free cash flow in FY2022 and FY2023, though conversion is improving with ¥2.7B of free cash flow projected for FY2026. ROE of 7-9% is adequate rather than compelling.

Income Statement

58Neutral

Balance Sheet

75Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue98.25B90.39B81.41B77.06B70.85B62.12B
Gross Profit11.64B10.66B9.89B9.53B8.66B7.74B
EBITDA3.94B3.32B3.10B2.92B3.11B2.45B
Net Income2.50B2.12B2.02B1.84B2.05B1.54B
Balance Sheet
Total Assets51.90B50.63B46.65B47.75B43.91B40.21B
Cash, Cash Equivalents and Short-Term Investments14.27B15.93B16.21B18.16B16.77B17.12B
Total Debt0713.06M0000
Total Liabilities28.71B27.34B22.58B24.37B21.12B19.07B
Stockholders Equity23.20B23.29B24.07B23.39B22.78B21.14B
Cash Flow
Free Cash Flow02.70B1.59B2.54B-525.17M673.91M
Operating Cash Flow02.93B2.06B3.04B445.15M1.85B
Investing Cash Flow0-132.31M-2.17B-219.47M1.92B-1.28B
Financing Cash Flow0-3.08B-1.83B-1.45B-1.16B-947.37M

WIN-Partners Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price1214.00

Price Trends

50DMA1243.80Negative
100DMA1263.08Negative
200DMA1281.95Negative

Market Momentum

MACD-2.79Positive
RSI44.02Neutral
STOCH9.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3183, the sentiment is Negative. The current price of 1214.00 is below the 20-day moving average (MA) of 1233.10, below the 50-day MA of 1243.80, and below the 200-day MA of 1281.95, indicating a bearish trend. The MACD of -2.79 indicates Positive momentum. The RSI at 44.02 is Neutral, neither overbought nor oversold. The STOCH value of 9.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3183.

WIN-Partners Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:3183 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:3183JP:318362NeutralJPY 34.85B13.38―4.45%13.99%17.93%
JP:4480JP:448058NeutralJPY 56.61B32.4911.30%―21.01%10.15%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:7071JP:707150NeutralJPY 25.66B20.00―1.53%1.93%-65.20%
JP:7061JP:706149NeutralJPY 2.86B-28.15――6.75%-119.69%
JP:7600JP:760045NeutralJPY 6.87B-4.42―6.51%-8.68%-75.03%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%JP:3183JP:4480JP:7061JP:7071JP:7600Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:3183 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:3183WIN-Partners Co., Ltd.1214.00-41.30-3.29%
JP:4480Medley, Inc.1780.00-870.00-32.83%
JP:7061Japan Hospice Holdings Inc.337.00-944.94-73.71%
JP:7071Amvis Holdings.Inc.261.00-172.57-39.80%
JP:7600Japan Medical Dynamic Marketing, Inc.261.00-205.88-44.10%

WIN-Partners Co., Ltd. Corporate Events

WIN-Partners Reports Strong First-Half Sales and Profit Growth

Nov 4, 2026

WIN-Partners Co., Ltd. reported strong consolidated results for the six months ended September 30, 2026, with net sales rising 18.0% year on year to ¥51.6 billion, operating profit increasing 40.9% to ¥2.1 billion, and profit attributable to owners o...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026